LT3736270T - Cistinės fibrozės transmembraninį laidumą reguliuojančių baltymų moduliatoriai ir jų naudojimo būdai - Google Patents

Cistinės fibrozės transmembraninį laidumą reguliuojančių baltymų moduliatoriai ir jų naudojimo būdai

Info

Publication number
LT3736270T
LT3736270T LTEP20183402.5T LT20183402T LT3736270T LT 3736270 T LT3736270 T LT 3736270T LT 20183402 T LT20183402 T LT 20183402T LT 3736270 T LT3736270 T LT 3736270T
Authority
LT
Lithuania
Prior art keywords
modulators
methods
cystic fibrosis
fibrosis transmembrane
conductance regulator
Prior art date
Application number
LTEP20183402.5T
Other languages
English (en)
Inventor
Robert J Altenbach
Andrew Bogdan
Sylvain COUTY
Nicolas Desroy
Gregory A. Gfesser
Philip R. Kym
Bo Liu
Thi Thu Trang Mai
Karine Fabienne MALAGU
Nuria Merayo Merayo
Olivier Laurent Picolet
Xenia B. Searle
Steven Emiel Van Der Plas
Xueqing Wang
Ming C. Yeung
Christopher Gaėtan HOUSSEMAN
Mathieu Rafaėl PIZZONERO
Original Assignee
Galapagos N.V.
Abbvie Overseas S.A R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos N.V., Abbvie Overseas S.A R.L. filed Critical Galapagos N.V.
Publication of LT3736270T publication Critical patent/LT3736270T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Sanitary Thin Papers (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Indole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
LTEP20183402.5T 2017-09-14 2018-09-13 Cistinės fibrozės transmembraninį laidumą reguliuojančių baltymų moduliatoriai ir jų naudojimo būdai LT3736270T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762558430P 2017-09-14 2017-09-14
US201762608846P 2017-12-21 2017-12-21

Publications (1)

Publication Number Publication Date
LT3736270T true LT3736270T (lt) 2021-08-25

Family

ID=63713961

Family Applications (3)

Application Number Title Priority Date Filing Date
LTEP20183405.8T LT3736267T (lt) 2017-09-14 2018-09-13 Cistinės fibrozės transmembraninį laidumą reguliuojančių baltymų moduliatoriai ir jų naudojimo būdai
LTEP18779798.0T LT3681864T (lt) 2017-09-14 2018-09-13 Cistinės fibrozės transmembraninio laidumo reguliatoriaus baltymų moduliatoriai ir jų naudojimo būdai
LTEP20183402.5T LT3736270T (lt) 2017-09-14 2018-09-13 Cistinės fibrozės transmembraninį laidumą reguliuojančių baltymų moduliatoriai ir jų naudojimo būdai

Family Applications Before (2)

Application Number Title Priority Date Filing Date
LTEP20183405.8T LT3736267T (lt) 2017-09-14 2018-09-13 Cistinės fibrozės transmembraninį laidumą reguliuojančių baltymų moduliatoriai ir jų naudojimo būdai
LTEP18779798.0T LT3681864T (lt) 2017-09-14 2018-09-13 Cistinės fibrozės transmembraninio laidumo reguliatoriaus baltymų moduliatoriai ir jų naudojimo būdai

Country Status (33)

Country Link
US (6) US10988454B2 (lt)
EP (4) EP3736270B1 (lt)
JP (4) JP7064072B2 (lt)
KR (1) KR20200086661A (lt)
CN (1) CN111954664A (lt)
AU (1) AU2018332512A1 (lt)
BR (1) BR112020005102A2 (lt)
CA (1) CA3074945A1 (lt)
CL (1) CL2020000664A1 (lt)
CO (1) CO2020004249A2 (lt)
CR (1) CR20200157A (lt)
CY (3) CY1123761T1 (lt)
DK (3) DK3736270T3 (lt)
EC (1) ECSP20021913A (lt)
ES (3) ES2887449T3 (lt)
HR (3) HRP20210099T1 (lt)
HU (3) HUE052873T2 (lt)
IL (1) IL273163A (lt)
LT (3) LT3736267T (lt)
MA (1) MA50240B1 (lt)
MD (3) MD3736267T2 (lt)
MX (1) MX2020002806A (lt)
PE (1) PE20210140A1 (lt)
PH (1) PH12020500509A1 (lt)
PL (3) PL3681864T4 (lt)
PT (3) PT3681864T (lt)
RS (3) RS61899B1 (lt)
RU (1) RU2020113350A (lt)
SG (1) SG11202002101RA (lt)
SI (3) SI3681864T1 (lt)
UA (1) UA125541C2 (lt)
WO (1) WO2019053634A1 (lt)
ZA (1) ZA202002363B (lt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4159717A1 (en) 2014-10-06 2023-04-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
PT3519401T (pt) 2016-09-30 2021-12-27 Vertex Pharma Modulador de regulador de condutância transmembranar de fibrose quística, composições farmacêuticas, métodos de tratamento e processo para fazer o modulador
SI3551622T1 (sl) 2016-12-09 2021-02-26 Vertex Pharmaceuticals Incorporated Modulatorji regulatorja transmembranske prevodnosti pri cistični fibrozi, farmacevtski sestavki, postopki zdravljenja in postopek izdelave modulatorja
WO2018227049A1 (en) 2017-06-08 2018-12-13 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
MA49631A (fr) 2017-07-17 2020-05-27 Vertex Pharma Méthodes de traitement de la fibrose kystique
AU2018309043B2 (en) 2017-08-02 2022-03-31 Vertex Pharmaceuticals Incorporated Processes for preparing pyrrolidine compounds
US10988454B2 (en) * 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
LT3697789T (lt) 2017-10-18 2021-12-10 Incyte Corporation Kondensuoti imidazolo dariniai, pakeisti tretinėmis hidroksigrupėmis, kaip pi3k-gama inhibitoriai
CA3078893A1 (en) 2017-10-19 2019-04-25 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of cftr modulators
MA51039A (fr) 2017-12-08 2020-10-14 Vertex Pharma Procédés pour préparer des modulateurs du régulateur de la conductance transmembranaire de la mucoviscidose
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
CN112004817B (zh) 2018-02-15 2023-06-23 弗特克斯药品有限公司 作为cftr的调节剂的大环化合物、其药物组合物、它们的用途和制备方法
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
EP3897832B1 (en) * 2018-12-18 2023-10-11 Novartis AG N-(pyridin-2-ylsulfonyl)cyclopropanecarboxamide derivatives and their use in the treatment of a cftr mediated disease
TW202115092A (zh) 2019-08-14 2021-04-16 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
TW202120517A (zh) 2019-08-14 2021-06-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
AU2020328028A1 (en) 2019-08-14 2022-03-17 Vertex Pharmaceuticals Incorporated Crystalline forms of CFTR modulators
EP4274828A1 (en) * 2021-01-06 2023-11-15 AbbVie Global Enterprises Ltd. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
US20220213041A1 (en) * 2021-01-06 2022-07-07 AbbVie Global Enterprises Ltd. Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB602426A (en) * 1945-10-24 1948-05-26 Geigy Ag J R Manufacture of aromatic acyl-sulphonamides
JP2004529855A (ja) * 2000-10-10 2004-09-30 スミスクライン ビーチャム コーポレーション 置換インドール類、そのような置換インドール類を含む医薬組成物及びＰＰＡＲ−γ結合剤としてのそれらの使用
WO2005120497A2 (en) 2004-06-04 2005-12-22 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
EP2522659A3 (en) 2004-06-24 2013-11-27 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
WO2008127399A2 (en) 2006-11-03 2008-10-23 Vertex Pharmaceuticals Incorporated Azaindole derivatives as cftr modulators
EP2170901B1 (en) 2007-05-25 2015-07-01 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
MX2010002319A (es) * 2007-08-29 2010-03-22 Schering Corp Derivados indolicos 2,3 sustituidos para el tratamiento de infecciones virales.
MX2010005356A (es) * 2007-11-16 2010-05-27 Schering Corp Derivados de indol 3-heterociclico sustituidos y metodos de uso de los mismos.
PL2444120T3 (pl) 2007-12-10 2018-02-28 Novartis Ag Spirocyklicze analogi amiloridu jako blokery ENac
JP5637859B2 (ja) 2007-12-13 2014-12-10 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 嚢胞性線維症膜コンダクタンスレギュレーターのモジュレーター
AU2009228307A1 (en) 2008-03-25 2009-10-01 The Regents Of The University Of California Water soluble small molecule inhibitors of the cystic fibrosis transmembrane conductance regulator
EP2358680B1 (en) 2008-10-23 2013-03-20 Vertex Pharmaceuticals Incorporated Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide
PL2365972T3 (pl) 2008-11-06 2015-05-29 Vertex Pharma Modulatory transporterów posiadających kasetę wiążącą ATP
US8367660B2 (en) 2008-12-30 2013-02-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CN102458122A (zh) * 2009-04-20 2012-05-16 人类健康研究所 含有哒嗪磺胺衍生物的化合物、组合物和方法
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
PT2624695E (pt) 2010-10-08 2015-12-01 Nivalis Therapeutics Inc Novos compostos de quinolina substituídos como inibidores de s-nitrosoglutationa redutase
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
ES2558457T3 (es) 2011-09-16 2016-02-04 Novartis Ag Compuestos heterocíclicos para el tratamiento de fibrosis quística
ES2882807T3 (es) 2011-09-16 2021-12-02 Novartis Ag Heterociclil carboxamidas N-sustituidas
WO2013043720A1 (en) 2011-09-20 2013-03-28 The University Of North Carolina At Chapel Hill Regulation of sodium channels by plunc proteins
BR112015027964B1 (pt) 2013-05-07 2023-01-10 Galapagos Nv Compostos moduladores do regulador de condutância transmembrana da fibrose cística (cftr), composições farmacêuticas compreendendo os mesmos e uso destes para o tratamento da fibrose cística
EP3030568B1 (en) 2013-08-08 2018-09-19 Galapagos NV Thieno[2,3-c]pyrans as cftr modulators
CN103484818A (zh) 2013-09-25 2014-01-01 京东方科技集团股份有限公司 蒸镀方法、蒸镀装置和发光器件
CA2942387A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr actvity
EP3116501A1 (en) 2014-03-13 2017-01-18 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
KR102132215B1 (ko) 2014-04-03 2020-07-09 삼성전자주식회사 자기 터널 접합 구조물 형성 방법 및 이를 이용한 자기 메모리 소자의 제조 방법
EP4159717A1 (en) 2014-10-06 2023-04-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
MX2017005663A (es) 2014-10-31 2018-03-01 Abbvie Sarl Tetrahidropiranos sustituidos y metodo de uso.
SG11201703391VA (en) 2014-10-31 2017-05-30 Abbvie S À R L Substituted chromanes and method of use
AU2016272702A1 (en) 2015-06-02 2017-12-21 Abbvie S.A.R.L. Substituted pyridines and method of use
US9840513B2 (en) 2015-07-16 2017-12-12 Abbvie S.Á.R.L. Substituted tricyclics and method of use
EP3359541B1 (en) 2015-10-09 2020-08-05 AbbVie Overseas S.à r.l. N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
MX2018013002A (es) 2016-04-26 2019-01-31 Abbvie Sarl Moduladores de la proteina reguladora de la conductancia transmembrana de la fibrosis quistica.
US10138227B2 (en) 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use
US9981910B2 (en) 2016-10-07 2018-05-29 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
US10399940B2 (en) 2016-10-07 2019-09-03 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
US10988454B2 (en) * 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use

Also Published As

Publication number Publication date
US10981890B2 (en) 2021-04-20
HUE055241T2 (hu) 2021-11-29
ES2887449T3 (es) 2021-12-22
MD3736270T2 (ro) 2021-11-30
DK3736267T3 (da) 2021-08-09
CN111954664A (zh) 2020-11-17
IL273163A (en) 2020-04-30
RS62185B1 (sr) 2021-08-31
CY1124615T1 (el) 2022-07-22
EP3681864B1 (en) 2020-10-28
US20200277274A1 (en) 2020-09-03
HUE052873T2 (hu) 2021-05-28
DK3736270T3 (da) 2021-08-09
MA50240A (fr) 2020-07-22
PL3736270T3 (pl) 2021-11-15
SI3736267T1 (sl) 2021-09-30
MA50240B1 (fr) 2021-03-31
US20200277273A1 (en) 2020-09-03
MD3736267T2 (ro) 2021-11-30
RS62190B1 (sr) 2021-08-31
EP3865474A1 (en) 2021-08-18
RU2020113350A3 (lt) 2022-04-14
PT3681864T (pt) 2021-02-25
PL3736267T3 (pl) 2021-11-15
JP7064074B2 (ja) 2022-05-10
CR20200157A (es) 2021-02-16
CO2020004249A2 (es) 2020-08-31
JP2022062093A (ja) 2022-04-19
SG11202002101RA (en) 2020-04-29
JP7064073B2 (ja) 2022-05-10
EP3681864A1 (en) 2020-07-22
ES2856751T3 (es) 2021-09-28
ES2881881T3 (es) 2021-11-30
US20210238159A1 (en) 2021-08-05
US10829473B2 (en) 2020-11-10
DK3681864T3 (da) 2021-01-25
RS61899B1 (sr) 2021-06-30
PT3736267T (pt) 2021-08-10
LT3681864T (lt) 2021-02-25
EP3736270A1 (en) 2020-11-11
ECSP20021913A (es) 2020-05-29
BR112020005102A2 (pt) 2020-09-24
KR20200086661A (ko) 2020-07-17
LT3736267T (lt) 2021-08-25
PH12020500509A1 (en) 2021-05-31
AU2018332512A1 (en) 2020-04-23
PE20210140A1 (es) 2021-01-21
ZA202002363B (en) 2021-06-30
HUE055050T2 (hu) 2021-10-28
US20200277275A1 (en) 2020-09-03
JP2022000461A (ja) 2022-01-04
JP2022000460A (ja) 2022-01-04
CL2020000664A1 (es) 2020-11-06
MD3681864T2 (ro) 2021-05-31
WO2019053634A1 (en) 2019-03-21
EP3736267A1 (en) 2020-11-11
HRP20210099T1 (hr) 2021-03-05
US10844041B2 (en) 2020-11-24
HRP20211200T1 (hr) 2021-10-29
PT3736270T (pt) 2021-08-10
PL3681864T3 (pl) 2021-05-17
SI3681864T1 (sl) 2021-08-31
SI3736270T1 (sl) 2021-09-30
CY1124401T1 (el) 2022-07-22
JP2020534360A (ja) 2020-11-26
EP3736270B1 (en) 2021-05-05
US20200277276A1 (en) 2020-09-03
EP3736267B1 (en) 2021-05-05
CY1123761T1 (el) 2022-05-27
US10844042B2 (en) 2020-11-24
PL3681864T4 (pl) 2021-05-17
US10988454B2 (en) 2021-04-27
UA125541C2 (uk) 2022-04-13
MX2020002806A (es) 2020-10-12
HRP20211198T1 (hr) 2021-10-29
JP7064072B2 (ja) 2022-05-10
RU2020113350A (ru) 2021-10-15
CA3074945A1 (en) 2019-03-21
US20190077784A1 (en) 2019-03-14

Similar Documents

Publication Publication Date Title
ZA202002363B (en) Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
IL261987B (en) Modulators of transmembrane conductance regulation in cystic fibrosis
HRP20201603T1 (hr) Modulatori regulatora transmembranske provodljivosti za cističnu fibrozu
IL275049B (en) Processes for preparing modulators to regulate cystic fibrosis transmembrane conductance
IL267048B (en) Modulatory modulation of transmembrane conductance in cystic fibrosis, pharmaceutical preparations, treatment methods, and a process for creating the modulator
IL265627B (en) Cystic fibrosis transmembrane conductance modulator, pharmaceutical preparations, methods of treatment and process for preparing the modulator
IL290408A (en) Cystic fibrosis transmembrane conductance modulators
IL252818A0 (en) Cyclopropanecarboxamides that modulate cystic fibrosis transmembrane conductance regulation
IL274763A (en) Methods for making cystic fibrosis transmembrane conductance modulator modulators
EP3724188C0 (en) PROGRANULIN MODULATORS AND METHODS OF USE THEREOF
EP3585420A4 (en) PEPTIDES AND METHODS OF TREATMENT OF DYSTROPHY RELATED CONDITIONS USING THEM